|February 12, 2003
|Expanded Clinical Data on AmpligenÒ in HIV Disease to be presented at the 16th International Conference on Antiviral Research
| Phase II B Study Evaluates Experimental Immunotherapy in “Holiday” Period when Antiviral Cocktails are Discontinued
Philadelphia, PA, Wednesday, February 12, 2003: Hemispherx Biopharma Inc. (Amex: HEB) announced that its clinical abstract entitled: “A Phase II B Prospective, Randomized, Control Study Evaluating AmpligenÒ During Structured Treatment Interruption (STI) of HAART in HIV Infection” has been selected for oral presentation at Session I on Monday, April 28, 2003 at 11:15 a.m. The selection of the clinical results for oral presentation at the distinguished congress of international researchers followed a rigorous peer-review process by medical scientists, unaffiliated with Hemispherx, with expertise in human immunology and viral infections.
The upcoming presentation will expand upon ongoing clinical trials referenced earlier at international meetings in Prague, Barcelona and Naples (Florida) within the last eight months. More details on the AmpligenÒ clinical study design, therapeutic end points and product safety parameters may be obtained from the U.S. Governmental web site: www.clinicaltrials.gov. The results will emphasize changes in the blood’s HIV concentration and the number and character of immune cells, performed in collaboration with LabCorp of America, Inc, the owner of ultrasensitive HIV measurement technology.
Active clinical research sites in the U.S. include those located in California, Connecticut, Florida (2 sites), New Jersey, New York, Pennsylvania and the District of Columbia (Washington, D.C.).
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the Immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web sit at http://www.hemispherx.net .
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Wesley Stanton, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.